Ozen Murat Eren, Yumru Mehmet, Savas Haluk A, Cansel Neslihan, Herken Hasan
Department of Psychiatry, Gaziantep University Faculty of Medicine, Gaziantep, Turkey.
World J Biol Psychiatry. 2007;8(1):42-4. doi: 10.1080/15622970600774202.
Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders. We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone. Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause. The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone. This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.
神经阻滞剂恶性综合征（NMS）是神经阻滞剂所致运动障碍中最罕见且最严重的一种。我们描述了一例与使用齐拉西酮相关的神经阻滞剂恶性综合征（NMS）病例。尽管传统神经阻滞剂更常与NMS相关，但像齐拉西酮这样的非典型抗精神病药物也可能是病因。该患者为一名24岁男性，有精神分裂症病史，在口服每日80毫克剂量的齐拉西酮治疗2天后出现了NMS的体征和症状。此病例是文献中报道的因齐拉西酮导致的最早（治疗第二天）的NMS。
